ENTA250117P7500
- 1.10
- 0.000.00%
Enanta Pharmaceuticals Newsroom
Enanta Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
H.C. Wainwright Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Cuts Target Price to $18
Enanta Pharma Analyst Ratings
Promising Virology Outcomes Boost Buy Rating for Enanta Pharmaceuticals Despite Symptom Assessment Concerns
JMP Securities Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $21
Evercore Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Cuts Target Price to $20
Oppenheimer Maintains Enanta Pharmaceuticals(ENTA.US) With Hold Rating, Maintains Target Price $14
Enanta Pharmaceuticals (ENTA) Gets a Hold From Oppenheimer
JMP Securities Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $21
Enanta Pharmaceuticals' RSV Platform Advances: Buy Rating Affirmed on Promising Clinical Data
Enanta Pharmaceuticals (ENTA) Receives a Sell From J.P. Morgan
Oppenheimer Maintains Enanta Pharmaceuticals(ENTA.US) With Hold Rating, Cuts Target Price to $14
Enanta Pharmaceuticals Is Maintained at Outperform by Baird
Enanta Pharma Analyst Ratings
Baird Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Cuts Target Price to $20
JMP Securities Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Cuts Target Price to $21
Enanta Pharmaceuticals: Promising RSV Developments and Strong Immunology Pipeline Justify Buy Rating
H.C. Wainwright Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $27
JMP Securities Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $22
Buy Rating for Enanta Pharmaceuticals Amid Reduced Competition and Promising Drug Trials